Dr. Michael Foggs, an Internationally Acclaimed Allergist, Becomes an Advisor to SRxA Allergy Group
Washington, DC, May 05, 2011 --(PR.com)-- Strategic Pharmaceutical Advisors (SRxA), a leading U.S. healthcare strategic marketing consulting and education firm, proudly announces that Michael B. Foggs MD, FAAAAI, DFACAAI, FCCP, has become an independent clinical Advisor to its Allergy Group.
Dr. Foggs is Chief of Advocate Medical Group of Advocate Health Care, one of the largest integrated healthcare networks in the United States. He graduated from Yale University with a Bachelor of Science degree in biology and cellular ultrastructure, and earned his medical degree from Harvard Medical School. He completed his internship and residency in internal medicine at Northwestern University Medical Center/Northwestern Memorial Hospital in Chicago, and his postdoctoral fellowship in Allergy and Immunology at the University of Pennsylvania School of Medicine and Hospitals as a National Institutes of Health Scholar.
Dr. Foggs is board certified in Internal Medicine and in Allergy and Immunology. He is a Distinguished Fellow of the American College of Allergy, Asthma & Immunology (DFACAAI). He is a Fellow of the American Academy of Allergy, Asthma & Immunology (FAAAAI) and the American College of Chest Physicians (FCCP). He has been named by Castle & Connolly Ltd. as one of Chicago's Top Doctors multiple times, and is listed by the Consumer's Research Council of America as one of America's Top Physicians. He is an authority on the management of asthma, chronic obstructive pulmonary disease (COPD), and allergic and immunologic disorders.
Dr. Foggs is past Chair of the Allergy, Asthma & Immunology Section of the National Medical Association (NMA) and a member of the NMA’s Consensus Panel on Asthma in the African American Community and the Task Force on Pay for Performance. He has served on the Methodology Committee and the Odyssey Faculty & Underserved Task Force of the American Academy of Allergy, Asthma & Immunology (AAAAI). He is a member of the Committee on the Underserved and the Health Outcomes, Education, Delivery & Quality (HEDQ) Committee and Plenary Subcommittee of the AAAAI.
Presently, he is Treasurer of the American College of Allergy, Asthma & Immunology (ACAAI), Chair of the Managed Care & Health Plans Committee of the ACAAI and serves on the Executive Committee, Marketing Task Force, Membership Recruitment Committee, ACORN (Fellows in Training Grant) Committee, Investment Oversight Committee, Publications Committee, and Communications Council of the ACAAI. He is also Chair of the Finance Committee and the Budget Committee of the ACAAI. He is a member of the Board of Regents of the ACAAI and a member of the Board of Directors of the Joint Council of Allergy, Asthma and Immunology (JCAAI). He is member of the Joint Task Force on Health Care Reform for allergy & immunology under the auspices of the JCAAI, the ACAAI, and the AAAAI and a member of the Asthma Special Committee of the World Allergy Organization (WAO). He is a member of the US Food and Drug Administration’s Pulmonary-Allergy Drug Advisory Committee (PADAC) and a recipient of the U.S. Food and Drug Administration Advisory Committee Distinguished Service Award. He is a member of the Expert Panel 3 of the National Asthma Education Prevention Program/National Heart Lung and Blood Institute, responsible for writing the Guidelines for the Diagnosis and Management of Asthma.
Dr. Foggs serves on the editorial board of the Annals of Allergy, Asthma & Immunology and is a reviewer for several academic journals. He is also on the editorial board for Allergy & Asthma Today. He is Co-Editor of Asthma Management and the Allergist: Better Outcomes at Lower Cost (the Blue Book).
“I am delighted to become an Advisor to SRxA and to support and contribute to the valuable educational projects and initiatives developed by this group,” commented Dr. Foggs.
Dr. Christos Efessiou, CEO of SRxA said, “I am pleased that Dr. Foggs has joined our team of Allergy Advisors. He is undoubtedly one of the most respected and sought-after Key Opinion Leaders and practicing specialists in this field. His involvement as an Advisor to SRxA, augments the intellectual assets of our team and enables us to offer our clients his wealth of expertise and guidance.”
SRxA operates on a unique business model that utilizes independent clinical teams of national and international Key Opinion Leaders who advise pharmaceutical and medical device clients in research, clinical, regulatory, education and business matters.
Strategic Allergy Advisors is a network of experts specializing in allergy, asthma, and clinical immunology, and is one of a growing number of specialties under the SRxA umbrella. In this group, Dr. Foggs joins other Leaders in the field including Drs. Eli Meltzer, Michael Kaliner, Bradley Chipps, William Storms, Michael Foggs, Allan Luskin, John Oppenheimer, Sheldon Spector, Don Bukstein, Warner Carr, Maeve O’Connor, and Russell Settipane.
In addition to Allergy other SRxA advisor groups focus in key therapeutic areas such as Pulmonary Diseases, Otolaryngology, Respiratory Medicine (Europe), Health Outcomes, Ophthalmology, Reproductive Endocrinology and Genetics, Ocular Medicine and Surgery, Aesthetics, and Behavioral Health. The company is headquartered in Washington, DC with offices in London and Hong Kong.
For more information, please contact Judi Miller at 202.316.8692 or jmiller@SRxA.com, or visit www.srxa.com
###
Dr. Foggs is Chief of Advocate Medical Group of Advocate Health Care, one of the largest integrated healthcare networks in the United States. He graduated from Yale University with a Bachelor of Science degree in biology and cellular ultrastructure, and earned his medical degree from Harvard Medical School. He completed his internship and residency in internal medicine at Northwestern University Medical Center/Northwestern Memorial Hospital in Chicago, and his postdoctoral fellowship in Allergy and Immunology at the University of Pennsylvania School of Medicine and Hospitals as a National Institutes of Health Scholar.
Dr. Foggs is board certified in Internal Medicine and in Allergy and Immunology. He is a Distinguished Fellow of the American College of Allergy, Asthma & Immunology (DFACAAI). He is a Fellow of the American Academy of Allergy, Asthma & Immunology (FAAAAI) and the American College of Chest Physicians (FCCP). He has been named by Castle & Connolly Ltd. as one of Chicago's Top Doctors multiple times, and is listed by the Consumer's Research Council of America as one of America's Top Physicians. He is an authority on the management of asthma, chronic obstructive pulmonary disease (COPD), and allergic and immunologic disorders.
Dr. Foggs is past Chair of the Allergy, Asthma & Immunology Section of the National Medical Association (NMA) and a member of the NMA’s Consensus Panel on Asthma in the African American Community and the Task Force on Pay for Performance. He has served on the Methodology Committee and the Odyssey Faculty & Underserved Task Force of the American Academy of Allergy, Asthma & Immunology (AAAAI). He is a member of the Committee on the Underserved and the Health Outcomes, Education, Delivery & Quality (HEDQ) Committee and Plenary Subcommittee of the AAAAI.
Presently, he is Treasurer of the American College of Allergy, Asthma & Immunology (ACAAI), Chair of the Managed Care & Health Plans Committee of the ACAAI and serves on the Executive Committee, Marketing Task Force, Membership Recruitment Committee, ACORN (Fellows in Training Grant) Committee, Investment Oversight Committee, Publications Committee, and Communications Council of the ACAAI. He is also Chair of the Finance Committee and the Budget Committee of the ACAAI. He is a member of the Board of Regents of the ACAAI and a member of the Board of Directors of the Joint Council of Allergy, Asthma and Immunology (JCAAI). He is member of the Joint Task Force on Health Care Reform for allergy & immunology under the auspices of the JCAAI, the ACAAI, and the AAAAI and a member of the Asthma Special Committee of the World Allergy Organization (WAO). He is a member of the US Food and Drug Administration’s Pulmonary-Allergy Drug Advisory Committee (PADAC) and a recipient of the U.S. Food and Drug Administration Advisory Committee Distinguished Service Award. He is a member of the Expert Panel 3 of the National Asthma Education Prevention Program/National Heart Lung and Blood Institute, responsible for writing the Guidelines for the Diagnosis and Management of Asthma.
Dr. Foggs serves on the editorial board of the Annals of Allergy, Asthma & Immunology and is a reviewer for several academic journals. He is also on the editorial board for Allergy & Asthma Today. He is Co-Editor of Asthma Management and the Allergist: Better Outcomes at Lower Cost (the Blue Book).
“I am delighted to become an Advisor to SRxA and to support and contribute to the valuable educational projects and initiatives developed by this group,” commented Dr. Foggs.
Dr. Christos Efessiou, CEO of SRxA said, “I am pleased that Dr. Foggs has joined our team of Allergy Advisors. He is undoubtedly one of the most respected and sought-after Key Opinion Leaders and practicing specialists in this field. His involvement as an Advisor to SRxA, augments the intellectual assets of our team and enables us to offer our clients his wealth of expertise and guidance.”
SRxA operates on a unique business model that utilizes independent clinical teams of national and international Key Opinion Leaders who advise pharmaceutical and medical device clients in research, clinical, regulatory, education and business matters.
Strategic Allergy Advisors is a network of experts specializing in allergy, asthma, and clinical immunology, and is one of a growing number of specialties under the SRxA umbrella. In this group, Dr. Foggs joins other Leaders in the field including Drs. Eli Meltzer, Michael Kaliner, Bradley Chipps, William Storms, Michael Foggs, Allan Luskin, John Oppenheimer, Sheldon Spector, Don Bukstein, Warner Carr, Maeve O’Connor, and Russell Settipane.
In addition to Allergy other SRxA advisor groups focus in key therapeutic areas such as Pulmonary Diseases, Otolaryngology, Respiratory Medicine (Europe), Health Outcomes, Ophthalmology, Reproductive Endocrinology and Genetics, Ocular Medicine and Surgery, Aesthetics, and Behavioral Health. The company is headquartered in Washington, DC with offices in London and Hong Kong.
For more information, please contact Judi Miller at 202.316.8692 or jmiller@SRxA.com, or visit www.srxa.com
###
Contact
SRxA Strategic Pharmaceutical Advisors, LLC
Judi Miller
202.316.8692
www.srxa.com
Judi Miller
202.316.8692
www.srxa.com
Contact
Categories